Comparison of adverse event costs of nivolumab combined with ipilimumab versus sunitinib for previously untreated metastatic renal cell carcinoma.

e16561Background: In the phase 3, open-label, randomized CheckMate 214 trial, nivolumab (N) combined with ipilimumab (I) (N 3 mg/kg + I 1 mg/kg every 3 weeks for 4 doses followed by N 3 mg/kg every...